Summary
Signal counts
Assets tracked: 4
Watchlist assets: 3
Registry stop assets: 1
Sponsor overview
Daiichi Sankyo
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT03248492 | https://clinicaltrials.gov/study/NCT03384940 | https://clinicaltrials.gov/study/NCT04132960 | https://clinicaltrials.gov/study/NCT07220616 | https://clinicaltrials.gov/study/NCT06330064 | https://clinicaltrials.gov/study/NCT07630974 | https://clinicaltrials.gov/study/NCT06362252 | https://clinicaltrials.gov/study/NCT05280470
Assets
Linked programs
- DS-8201a: Registry Stop Signal (5/5)
- DS3790a: Low Signal (1/5)
- Ifinatamab deruxtecan: Operational Burden Signal (2/5)
- Ifinatamab Deruxtecan (I-DXd): Watchlist Signal (2/5)